Cytos Biotechnology CYT003 Hinges On Trial Results

13-01-2014 Investing.comComments (0)

BiotechnologyCytos Biotechnology

Cytos Biotechnology's, (CYTN) investment case hinges on key asset CYT003, currently in a Phase IIb trial in allergic asthma. The study is due to report initial data in Q214, with full results in Q115. A positive outcome should facilitate either ...

Read more on Investing.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top